drugset / Trial / NCT02805608

uPAR PET/CT and FDG PET/MRI for Preoperative Staging of Bladder Cancer

NCT02805608

Phase 2 Unknown 40 enrolled Rigshospitalet, Denmark
NaSingle-groupOpen-labelDiagnostic

Summary

The sensitivity and specificity of uPAR PET/CT with the radioligand 68GaNOTA-AE105 and FDG PET/MRI for preoperative detection of regional lymph node metastases in urinary bladder cancer

Timeline

Start
2016-09
Primary completion
2019-01
Completion
2019-01

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-FDG Diagnostic / imaging agent Intravenous
Subject 68Ga-NOTA-AE105 Peptide Intravenous